WO2023154811A3 - Transcriptional enhanced associate domain (tead) degraders and uses thereof - Google Patents

Transcriptional enhanced associate domain (tead) degraders and uses thereof Download PDF

Info

Publication number
WO2023154811A3
WO2023154811A3 PCT/US2023/062307 US2023062307W WO2023154811A3 WO 2023154811 A3 WO2023154811 A3 WO 2023154811A3 US 2023062307 W US2023062307 W US 2023062307W WO 2023154811 A3 WO2023154811 A3 WO 2023154811A3
Authority
WO
WIPO (PCT)
Prior art keywords
tead
transcriptional
degraders
compounds
enhanced
Prior art date
Application number
PCT/US2023/062307
Other languages
French (fr)
Other versions
WO2023154811A2 (en
Inventor
Nathanael S. Gray
Tinghu Zhang
Wenzhi JI
Wenchao Lu
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The Leland Stanford Junior University filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Publication of WO2023154811A2 publication Critical patent/WO2023154811A2/en
Publication of WO2023154811A3 publication Critical patent/WO2023154811A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed herein are bispecific compounds that target and degrade transcriptional enhanced associate domain (TEAD) transcription factors, pharmaceutical compositions comprising the compounds, and methods of using the compounds, e.g., to treat diseases and disorders characterized or mediated by TEAD transcription factor activity.
PCT/US2023/062307 2022-02-09 2023-02-09 Transcriptional enhanced associate domain (tead) degraders and uses thereof WO2023154811A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263308265P 2022-02-09 2022-02-09
US63/308,265 2022-02-09

Publications (2)

Publication Number Publication Date
WO2023154811A2 WO2023154811A2 (en) 2023-08-17
WO2023154811A3 true WO2023154811A3 (en) 2023-09-14

Family

ID=87565118

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/062307 WO2023154811A2 (en) 2022-02-09 2023-02-09 Transcriptional enhanced associate domain (tead) degraders and uses thereof

Country Status (1)

Country Link
WO (1) WO2023154811A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020243423A1 (en) * 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
US20210238154A1 (en) * 2018-05-16 2021-08-05 Vivace Therapeutics, Inc. Oxadiazole compounds
WO2021178339A1 (en) * 2020-03-04 2021-09-10 Genentech, Inc. Heterobifunctional molecules as tead inhibitors
WO2022120355A1 (en) * 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead degraders and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210238154A1 (en) * 2018-05-16 2021-08-05 Vivace Therapeutics, Inc. Oxadiazole compounds
WO2020243423A1 (en) * 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2021178339A1 (en) * 2020-03-04 2021-09-10 Genentech, Inc. Heterobifunctional molecules as tead inhibitors
WO2022120355A1 (en) * 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead degraders and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TANG ET AL.: "Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma", MOLECULAR CANCER THERAPEUTICS, vol. 20, June 2021 (2021-06-01), pages 986 - 998, XP055875212, DOI: 10.1158/1535-7163.MCT-20-0717 *

Also Published As

Publication number Publication date
WO2023154811A2 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
WO2020092667A8 (en) 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
WO2020102646A3 (en) Inhibitors of arg1 and/or arg2
MX2022005775A (en) Therapeutic compounds and methods of use.
MX2021012706A (en) Dihydroorotate dehydrogenase inhibitors.
WO2019226213A3 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
EP4252755A3 (en) Therapeutic compounds
WO2020021480A3 (en) Compositions and methods for treating the eye
MX2022006176A (en) Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor.
WO2022175746A8 (en) Tyk2 inhibitors and uses thereof
WO2021100029A3 (en) Prodrugs of fulvestrant
WO2020231739A3 (en) Compounds and methods for treating cancer
WO2020068950A8 (en) Hdac1,2 inhibitors
MX2022011697A (en) Cyclophilin inhibitors and uses thereof.
WO2023278325A8 (en) Bifunctional compounds that degrade alk and uses thereof
WO2023154811A3 (en) Transcriptional enhanced associate domain (tead) degraders and uses thereof
WO2023122782A3 (en) Indoles, indazoles, and related analogs for inhibiting yap/taz-tead
WO2023122780A3 (en) 2-pyrazole anilines and related analogs for inhibiting yap/taz-tead
MX2022012404A (en) Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases.
MX2020013805A (en) Pyridopyrimidinone derivatives for use as axl inhibitors.
WO2021262636A3 (en) Compounds for targeted degradation of interleukin-2-inducible t-cell kinase and methods of use
MX2023003725A (en) Pharmaceutical compositions and methods for prevention and/or treatment of inflammation.
WO2023122783A3 (en) Tetrahydropyrazolopyrimidines and related analogs for inhibiting yap/taz-tead
WO2023122781A3 (en) Tetrahydrobenzoazepinones and related analogs for inhibiting yap/taz-tead
AU2020904651A0 (en) Compositions and methods for prevention and treatment of cardiovascular disease.
WO2024006956A3 (en) Deubiquitinase inhibitors and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23753663

Country of ref document: EP

Kind code of ref document: A2